Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma at the AACR Annual Meeting 2022
/PRNewswire/ -- Omega Therapeutics (NASDAQ: OMGA) (Omega), a development-stage biotechnology company pioneering the first systematic approach to use mRNA...
Source: prnewswire.com